What is the recommended use and dosing regimen of N‑acetylcysteine (NAC) for patients with acute alcoholic hepatitis or severe alcohol‑related liver injury?

NAC in Alcohol Toxicity

For severe alcoholic hepatitis (Maddrey DF ≥32), consider adding intravenous N-acetylcysteine to corticosteroids to reduce 1-month mortality, though this combination does not improve long-term survival.

Context and Evidence Quality

The most recent and highest-quality guideline evidence comes from the 2022 French Association for the Study of the Liver 1, which provides a nuanced recommendation based on a single pivotal randomized trial. This represents the current state of evidence: promising short-term benefits without long-term survival improvement.

When to Use NAC in Alcoholic Hepatitis

Indication

• Severe alcoholic hepatitis with Maddrey Discriminant Function (mDF) ≥32 or MELD >20
• Used as combination therapy with corticosteroids, not as monotherapy
• The 2022 French guidelines classify this as G2+ (weak agreement) specifically because it was evaluated in only one trial and did not meet its primary 6-month endpoint 1

Dosing Regimen (When Used)

Based on the landmark trial 2 and supported by guidelines 1, 3:

Intravenous NAC Protocol:

• Day 1:
  • Loading: 150 mg/kg in 250 mL 5% dextrose over 30 minutes
  • Then: 50 mg/kg in 500 mL 5% dextrose over 4 hours
  • Then: 100 mg/kg in 1000 mL 5% dextrose over 16 hours
• Days 2-5: 100 mg/kg/day in 1000 mL 5% dextrose over 24 hours

Given concurrently with:

• Prednisolone 40 mg/day OR methylprednisolone 32 mg/day for 28 days 1

Evidence Summary and Limitations

What NAC Does Accomplish

The combination of NAC + corticosteroids versus corticosteroids alone 2:

• Reduces 1-month mortality: 8% vs 24% (p=0.006)
• Reduces hepatorenal syndrome deaths: 9% vs 22% (p=0.02)
• Reduces infection rates (p=0.001)

What NAC Does NOT Accomplish

• No improvement in 6-month survival: 27% vs 38% (p=0.07) - the primary endpoint 2
• No improvement in 3-month survival: 22% vs 34% (p=0.06) 4

Divergent Evidence

The 2013 Korean guidelines 4 state that "N-acetylcysteine has not yet been found to be effective as a treatment for alcoholic hepatitis" and call for further research. However, the 2022 French guidelines 1 and 2020 AASLD guidance 3 acknowledge the short-term benefit while noting the lack of long-term efficacy.

A 2025 meta-analysis 5 found moderate certainty evidence supporting NAC + corticosteroids over corticosteroids alone at 28 days (RR 0.35,95% CI 0.16-0.78), but this still reflects the same short-term benefit pattern.

Clinical Decision Algorithm

Step 1: Confirm severe alcoholic hepatitis (mDF ≥32 or MELD >20)

Step 2: Exclude contraindications to corticosteroids:

• Active uncontrolled infection
• Active GI bleeding
• Renal failure (though NAC may help prevent hepatorenal syndrome)

Step 3: If corticosteroids are appropriate:

• Consider adding NAC if goal is to maximize 1-month survival and reduce hepatorenal syndrome risk
• Use corticosteroids alone if prioritizing simplicity and acknowledging that long-term outcomes are equivalent

Step 4: Monitor response at day 7 with Lille score

• Lille ≤0.45: Continue treatment
• Lille >0.45: Non-responder; consider early liver transplantation evaluation 1

Important Caveats

NAC is NOT indicated for:

• Non-severe alcoholic hepatitis (mDF <32)
• Monotherapy - always combine with corticosteroids if used 4
• Long-term survival improvement - abstinence remains the primary determinant of long-term outcomes 1

Common Pitfall

Do not confuse this indication with acetaminophen-induced acute liver failure, where NAC is the primary antidote with clear mortality benefit 6, 7. The FDA-approved indication for IV NAC is specifically for acetaminophen toxicity, not alcoholic hepatitis 7.

Safety Profile

NAC is generally well-tolerated with:

• Occasional nausea/vomiting
• Rare urticaria or bronchospasm (manageable with antihistamines) 6
• No increased adverse events compared to corticosteroids alone 2

Practical Recommendation

In real-world practice, the decision to add NAC should weigh:

• The meaningful reduction in 1-month mortality (16% absolute risk reduction)
• The reduction in hepatorenal syndrome (a devastating complication)
• The lack of long-term benefit
• The requirement for 5 days of IV infusion
• Resource availability and patient tolerance

For patients with severe alcoholic hepatitis who can tolerate IV therapy and where reducing early mortality is paramount, adding NAC to corticosteroids is reasonable 1, 3. However, this remains a weak recommendation requiring confirmatory studies, and corticosteroids alone remain an acceptable standard of care 4.